학술논문
Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.
Document Type
Academic Journal
Author
Dobarro D; Hospital Álvaro Cunqueiro, Complexo Hospitalario Universitario de Vigo, Vigo, Spain.; Donoso-Trenado V; Hospital Universitari i Politècnic La Fe, Valencia, Spain.; Solé-González E; Hospital Clinic i Provincial, Barcelona, Spain.; Moliner-Abós C; Hospital de la Santa Creu i Sant Pau, IIB SANT PAU, Barcelona, Spain.; Garcia-Pinilla JM; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Ciber-Cardiovascular, Instituto de Salud Carlos III, Departamento de Medicina y Dermatología, Universidad de Málaga, Malaga, Spain.; Lopez-Fernandez S; Hospital Universitario Virgen de las Nieves, ibs. GRANADA, Granada, Spain.; Ruiz-Bustillo S; Hospital del Mar, Barcelona, Spain.; Diez-Lopez C; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Hospital Universitari de Bellvitge - BIOHEART Research IDIBELL, Hospitalet del Llobregat, Barcelona, Spain.; Castrodeza J; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Méndez-Fernández AB; Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Vaqueriza-Cubillo D; Hospital Universitario Infanta Leonor, Madrid, Spain.; Cobo-Marcos M; Hospital Universitario Puerta de Hierro, IDIPHISA, Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.; Tobar J; Hospital Clínico Universitario de Valladolid, Valladolid, Spain.; Sagasti-Aboitiz I; Hospital Universitario de Cruces, Bizkaia, Spain.; Rodriguez M; Complejo Hospitalario Universitario de León, León, Spain.; Escolar V; Hospital de Basurto, Bilbao, Spain.; Abecia A; Hospital de Navarra, Pamplona, Spain.; Codina P; Hospital Germans Trias i Pujol, Badalona, Spain.; Gómez-Otero I; Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.; Pastor F; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.; Marzoa-Rivas R; Hospital Arquitecto Marcide, Ferrol, Spain.; González-Babarro E; Hospital de Montecelo, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.; de Juan-Baguda J; Hospital Universitario 12 de Octubre, IMAS12, Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Departamento de Medicina, Facultad de ciencias biomédicas y de la salud, Universidad Europea de Madrid, Madrid, Spain.; Melendo-Viu M; Hospital Álvaro Cunqueiro, Complexo Hospitalario Universitario de Vigo, Vigo, Spain.; de Frutos F; Hospital Universitario Puerta de Hierro, IDIPHISA, Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.; Gonzalez-Costello J; Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Hospital Universitari de Bellvitge - BIOHEART Research IDIBELL, Hospitalet del Llobregat, Barcelona, Spain.
Source
Publisher: John Wiley & Sons Ltd on behalf of the European Society of Cardiology Country of Publication: England NLM ID: 101669191 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2055-5822 (Electronic) Linking ISSN: 20555822 NLM ISO Abbreviation: ESC Heart Fail Subsets: MEDLINE
Subject
Language
English
Abstract
Aim: Patients with advanced heart failure (AHF) who are not candidates to advanced therapies have poor prognosis. Some trials have shown that intermittent levosimendan can reduce HF hospitalizations in AHF in the short term. In this real-life registry, we describe the patterns of use, safety and factors related to the response to intermittent levosimendan infusions in AHF patients not candidates to advanced therapies.
Methods and Results: Multicentre retrospective study of patients diagnosed with advanced heart failure, not HT or LVAD candidates. Patients needed to be on the optimal medical therapy according to their treating physician. Patients with de novo heart failure or who underwent any procedure that could improve prognosis were not included in the registry. Four hundred three patients were included; 77.9% needed at least one admission the year before levosimendan was first administered because of heart failure. Death rate at 1 year was 26.8% and median survival was 24.7 [95% CI: 20.4-26.9] months, and 43.7% of patients fulfilled the criteria for being considered a responder lo levosimendan (no death, heart failure admission or unplanned HF visit at 1 year after first levosimendan administration). Compared with the year before there was a significant reduction in HF admissions (38.7% vs. 77.9%; P < 0.0001), unplanned HF visits (22.7% vs. 43.7%; P < 0.0001) or the combined event including deaths (56.3% vs. 81.4%; P < 0.0001) during the year after. We created a score that helps predicting the responder status at 1 year after levosimendan, resulting in a score summatory of five variables: TEER (+2), treatment with beta-blockers (+1.5), Haemoglobin >12 g/dL (+1.5), amiodarone use (-1.5) HF visit 1 year before levosimendan (-1.5) and heart rate >70 b.p.m. (-2). Patients with a score less than -1 had a very low probability of response (21.5% free of death or HF event at 1 year) meanwhile those with a score over 1.5 had the better chance of response (68.4% free of death or HF event at 1 year). LEVO-D score performed well in the ROC analysis.
Conclusion: In this large real-life series of AHF patients treated with levosimendan as destination therapy, we show a significant decrease of heart failure events during the year after the first administration. The simple LEVO-D Score could be of help when deciding about futile therapy in this population.
(© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
Methods and Results: Multicentre retrospective study of patients diagnosed with advanced heart failure, not HT or LVAD candidates. Patients needed to be on the optimal medical therapy according to their treating physician. Patients with de novo heart failure or who underwent any procedure that could improve prognosis were not included in the registry. Four hundred three patients were included; 77.9% needed at least one admission the year before levosimendan was first administered because of heart failure. Death rate at 1 year was 26.8% and median survival was 24.7 [95% CI: 20.4-26.9] months, and 43.7% of patients fulfilled the criteria for being considered a responder lo levosimendan (no death, heart failure admission or unplanned HF visit at 1 year after first levosimendan administration). Compared with the year before there was a significant reduction in HF admissions (38.7% vs. 77.9%; P < 0.0001), unplanned HF visits (22.7% vs. 43.7%; P < 0.0001) or the combined event including deaths (56.3% vs. 81.4%; P < 0.0001) during the year after. We created a score that helps predicting the responder status at 1 year after levosimendan, resulting in a score summatory of five variables: TEER (+2), treatment with beta-blockers (+1.5), Haemoglobin >12 g/dL (+1.5), amiodarone use (-1.5) HF visit 1 year before levosimendan (-1.5) and heart rate >70 b.p.m. (-2). Patients with a score less than -1 had a very low probability of response (21.5% free of death or HF event at 1 year) meanwhile those with a score over 1.5 had the better chance of response (68.4% free of death or HF event at 1 year). LEVO-D score performed well in the ROC analysis.
Conclusion: In this large real-life series of AHF patients treated with levosimendan as destination therapy, we show a significant decrease of heart failure events during the year after the first administration. The simple LEVO-D Score could be of help when deciding about futile therapy in this population.
(© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)